SG11201909676WA - Treatment of her2 positive cancers - Google Patents

Treatment of her2 positive cancers

Info

Publication number
SG11201909676WA
SG11201909676WA SG11201909676WA SG11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA
Authority
SG
Singapore
Prior art keywords
international
tucatinib
trastuzumab
suite
pct
Prior art date
Application number
Inventor
Scott Peterson
Luke Walker
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201909676WA publication Critical patent/SG11201909676WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

IS- Vehicle Control Tucatinib: nv/kg/close, PO, BID x26 -a- Trastuzumab: 20 mg/kg/dose, P. Q3D x9 Tucatinib + Trastuzumab FIG. 5C Anti-Tumor Effect of Tucatinib and Trastuzumab in Gastric Cancer PDX GXA 3054 Group Mean (n=10) Tumor Volume ± SD 500 'E 400 E 300 200 8 100 14 21 28 Study Day 1-1 1-1 1-1 00 1-1 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit VIII °nolo Holollm olollm mom° oimIE (10) International Publication Number WO 2018/201016 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 31/7068 (2006.01) A61K 31/517 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/029899 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,872 28 April 2017 (28.04.2017) US (71) Applicant: CASCADIAN THERAPEUTICS, INC. [US/US]; 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). (72) Inventor: PETERSON, Scott; c/o Cascadian Therapeu- tics, Inc., 2601 4th Ave., Suite 500, Seattle, Washington 98121 (US). (74) Agent: ZYLSTRA, Eric J. et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: TREATMENT OF HER2 POSITIVE CANCERS (57) : In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
SG11201909676W 2017-04-28 2018-04-27 Treatment of her2 positive cancers SG11201909676WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491872P 2017-04-28 2017-04-28
PCT/US2018/029899 WO2018201016A1 (en) 2017-04-28 2018-04-27 Treatment of her2 positive cancers

Publications (1)

Publication Number Publication Date
SG11201909676WA true SG11201909676WA (en) 2019-11-28

Family

ID=62165692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909676W SG11201909676WA (en) 2017-04-28 2018-04-27 Treatment of her2 positive cancers

Country Status (13)

Country Link
US (3) US11207324B2 (en)
EP (1) EP3615067A1 (en)
JP (2) JP7328151B2 (en)
KR (1) KR20200014298A (en)
CN (1) CN111032082A (en)
AU (2) AU2018258663B2 (en)
BR (1) BR112019022280A2 (en)
CA (1) CA3060407A1 (en)
EA (1) EA201992573A1 (en)
MA (1) MA49059A (en)
SG (1) SG11201909676WA (en)
WO (1) WO2018201016A1 (en)
ZA (1) ZA201907225B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992573A1 (en) * 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. TREATMENT OF HER2-POSITIVE MALIGNANT NEOPLASMS
TW202042820A (en) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 Methods of treating breast cancer with tucatinib
KR20220019724A (en) 2019-06-11 2022-02-17 아이오 테라퓨틱스, 인크. Use of RXR agonists in the treatment of HER2+ cancer
US20240092936A1 (en) * 2019-10-21 2024-03-21 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
IL298538A (en) * 2020-05-29 2023-01-01 Seagen Inc Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
MX2023003406A (en) * 2020-09-28 2023-03-31 Seagen Inc Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody.
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
ATE154240T1 (en) 1992-03-12 1997-06-15 Alkermes Inc ACTH CONTAINING MICRO SPHERES WITH CONTROLLED RELEASE
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
PT1660090E (en) 2003-08-14 2013-01-11 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
BRPI0511754A (en) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd use of a compound or salts or solvates thereof
US8648087B2 (en) 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EP2205077A4 (en) * 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
TWI574698B (en) 2008-03-18 2017-03-21 建南德克公司 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP3670539A1 (en) * 2009-11-13 2020-06-24 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
ES2701929T3 (en) * 2011-05-19 2019-02-26 Laboratory Corp America Holdings Methods to determine the probability of survival and to predict the probability of metastasis in cancer
CA3114454C (en) 2011-10-14 2022-11-29 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-.alpha.]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
NZ756264A (en) 2012-03-23 2022-09-30 Array Biopharma Inc Treatment of brain cancer
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3445768A4 (en) * 2016-04-19 2019-12-18 The Regents of The University of California Erbb inhibitors and uses thereof
EA201992573A1 (en) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. TREATMENT OF HER2-POSITIVE MALIGNANT NEOPLASMS
WO2019241599A1 (en) 2018-06-14 2019-12-19 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
TW202042820A (en) 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 Methods of treating breast cancer with tucatinib
US20240092936A1 (en) 2019-10-21 2024-03-21 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP2023517078A (en) 2020-03-11 2023-04-21 シージェン インコーポレイテッド Methods of treating cancers with HER2 mutations using tucatinib

Also Published As

Publication number Publication date
MA49059A (en) 2021-03-24
CA3060407A1 (en) 2018-11-01
JP2020517696A (en) 2020-06-18
ZA201907225B (en) 2023-11-29
JP7328151B2 (en) 2023-08-16
KR20200014298A (en) 2020-02-10
EA201992573A1 (en) 2020-04-06
AU2018258663B2 (en) 2022-08-04
JP2023145689A (en) 2023-10-11
US11207324B2 (en) 2021-12-28
WO2018201016A1 (en) 2018-11-01
AU2018258663A1 (en) 2019-11-14
US11666572B2 (en) 2023-06-06
AU2022241509A1 (en) 2022-10-27
US20230390290A1 (en) 2023-12-07
US20220168303A1 (en) 2022-06-02
EP3615067A1 (en) 2020-03-04
US20200188401A1 (en) 2020-06-18
BR112019022280A2 (en) 2020-05-19
CN111032082A (en) 2020-04-17

Similar Documents

Publication Publication Date Title
SG11201909676WA (en) Treatment of her2 positive cancers
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201901126UA (en) Combination therapy for cancer
SG11201908131RA (en) Benzazepine compounds, conjugates, and uses thereof
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201905622VA (en) Subcutaneous her2 antibody formulations
SG11201808125RA (en) Methods for solid tumor treatment
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer
SG11201908788YA (en) Combinations of chk1- and wee1 - inhibitors
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907804QA (en) Pharmaceutical composition comprising selexipag